It has been demonstrated for tomoregulin (TENB2), a promising molecular target for prostate cancer that is also expressed in healthy gastrointestinal tissue (GIT), that pre-administration of the unconjugated TENB2 mAb, at a suitable dose level, saturates the low-to-moderate peripheral antigen expression in the GIT while maintaining tumor uptake and efficacy of the TEN2B-ADC in antigen overexpressing rodent explant models [11]. This evidence concerns the gene TMEFF2 and prostate cancer.